Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

May 27, 2022

  • Pharmaceuticals
  • Corporate

Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd. announced that the Tokyo District Court has today rendered judgment to dismiss the plaintiff’s claim in the lawsuit filed on May 29, 2020 regarding the generic drugs to an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule) against Sawai Pharmaceutical Co., Ltd. (hereafter, Sawai) and Nichi-Iko Pharmaceutical Co., Ltd. (hereafter, Nichi-Iko).

  1. Date of Complaint and Judgment
    May 29, 2020 Complaint from Chugai Pharmaceutical Co., Ltd.
    May 27, 2022 Rendered judgment by the Tokyo District Court
  2. Reasons for the Action

    On February 17, 2020, Sawai and Nichi-Iko respectively obtained approval from the Ministry of Health, Labour and Welfare for their generic drugs to Edirol Capsule distributed by Chugai. Chugai alleged that the generic drugs to Edirol Capsule infringe its use patent right (patent number 5969161) which is for pharmaceutical composition for suppressing forearm fractures, and filed patent infringement lawsuit with the Tokyo District Court based on its right seeking injunction of manufacturing, transferring, importing, and offering of any transfer regarding the generic drugs, and disposal of stock. Today, the Tokyo District Court rendered judgment to dismiss the plaintiff’s claim.

  3. Defendants
    1. Name: Sawai Pharmaceutical Co., Ltd.
      Address: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
    2. Name: Nichi-Iko Pharmaceutical Co., Ltd.
      Address: 1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan
  4. Prospects
    No changes are expected to Chugai’s financial prospects at this point. We will consider future measures based on the contents of the judgment.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top